Telescope Innovations upbeat for 2026

Executive Summary

• Telescope Innovations Corp. provided a strategic update highlighting the accelerating commercial adoption of self-driving labs (SDLs) and physical AI, following a successful deployment for the Korea Pharmaceutical and Biopharmaceutical Manufacturers Association (KPBMA).
• The company positioned its SDL technology as a critical enabler for the emerging "Physical AI" trend, citing industry reports from Gartner and Global X that predict significant growth in domain-specific AI and automation-driven industrial supercycles.
• CEO Henry Dubina stated that fiscal year 2025 marked a transition from development to commercialization, citing record sales and funded programs with global pharmaceutical leaders, including a multiyear project with Pfizer.

Key Details

• Recent Deployment: Successful deployment of a pharmaceutical SDL for the Korea Pharmaceutical and Biopharmaceutical Manufacturers Association (KPBMA), serving as a blueprint for accelerating R&D in advanced materials.
• Technology Definition: SDLs are defined as fixed-position physical AI platforms integrating robotics, in-line analytics, and machine learning for continuous, autonomous closed-loop workflows, distinct from mobile labs.
• Market Validation & Trends:
  • Gartner (Oct. 20, 2025): Identified physical AI as a top strategic technology trend for 2026.
  • Gartner Prediction: By 2028, over 50% of enterprise AI models will be domain-specific, requiring the high-quality "ground truth" data generated by Telescope’s SDLs.
  • Global X (May 14, 2025): Suggested the economy has entered an "Automation Age," with digital intelligence and physical hardware triggering a new industrial supercycle.
  • Grand View Research (Dec. 2025): Projected the global lab-automation market to reach approximately $18.39 billion (U.S.) by 2033, growing at a CAGR of 9.3%.
• Commercial Momentum:
  • CEO Henry Dubina cited "record sales performance" in fiscal year 2025.
  • Mention of funded SDL programs with global pharmaceutical leaders.
  • Specific mention of a multiyear financed SDL development project with Pfizer.
• Target Verticals:
  • Pharmaceuticals: Validated by KPBMA installation and Pfizer project.
  • Industrial Chemistry: Rapid screening for catalysts, polymers, advanced materials, and specialty coatings.
  • Agriculture and Energy: Optimization of fermentation, battery materials, and carbon-capture reactions.
  • Space/Off-Earth: Potential for microgravity research and life-support chemistry.

Notable Quotes

• "Telescope is uniquely positioned at the intersection of chemical engineering and physical AI," said Henry Dubina, chief executive officer of Telescope Innovations. "From our funded SDL programs with global pharmaceutical leaders to our record sales performance this past year, fiscal year 2025 marked an important transition from development to commercialization. Our successful installation in Korea proves that our SDL architecture is a ready-to-deploy industrial asset that delivers the high-quality, domain-specific data now required by the world's leading organizations to maintain their competitive edge."